Tandem Diabetes Care, Inc.TNDM

$15.30-0.10 (-0.65%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$1B
Small-cap
+469%
2016 — today
10-Year Price
-75%
2016 — today
52-Week Range
$10.12$28.26
Current $15.30· 29%

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Valuation in context

P/E ratio
-10.9
N/A
Not meaningful — company is unprofitable
P/B ratio
7.9
Below average
Below the 10-year average
FCF Yield
-0.4%
Around average
Around the 10-year average
Free · No credit card needed

Get alerted when TNDM is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.